Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial.

doi:10.1080/13506129.2018.1503593

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis - 1 Sept 2018

Waddington-Cruz Marcia, Ackermann Elizabeth J, Polydefkis Michael, Heitner Stephen B, Dyck Peter J, Barroso Fabio A, Wang Annabel K, Berk John L, Dyck P James B, Monia Brett P, Hughes Steven G, Tai Li, Jesse Kwoh T, Jung Shiangtung W, Coelho Teresa, Benson Merrill D, Gertz Morie A

Abstract excerpt

BACKGROUND: Hereditary transthyretin (ATTRm) amyloidosis is a rare, progressive and fatal disease with a range of clinical manifestations. OBJECTIVE: This study comprehensively evaluates disease characteristics in a large, diverse cohort of patients with ATTRm amyloidosis. METHODS: Adult patients (N = 172) with Stage 1 or Stage 2 ATTRm amyloidosis who had polyneuropathy were screened and enrolled across 24...

Topics

Adult
Aged
Aged, 80 and over
Amyloid Neuropathies, Familial
Cardiomyopathies
Female
Humans
Male
Middle Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Mutation

Oligonucleotides, Antisense

Polyneuropathies

Prealbumin

Quality of Life

Young Adult

Source

Open in PubMed

Identifiers

PMID: 30169969
DOI: 10.1080/13506129.2018.1503593

Genes

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial.PMID 30169969Read ↗

Canadian Guidelines for Hereditary Transthyretin Amyloidosis Polyneuropathy ManagementSemantic proximity Read ↗

Guideline of transthyretin-related hereditary amyloidosis for cliniciansSemantic proximity Read ↗

Transthyretin amyloidosis: an under-recognized neuropathy and cardiomyopathySemantic proximity Read ↗

Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update.Semantic proximity Read ↗

Neuropathy Associated with Systemic Amyloidosis.Semantic proximity Read ↗

Transthyretin Amyloid Cardiomyopathy–2025 Update: Current Diagnostic Approaches and Emerging Therapeutic OptionsSemantic proximity Read ↗

Hereditary transthyretin amyloidosis: a comprehensive review with a focus on peripheral neuropathySemantic proximity Read ↗

Detailed clinical, physiological and pathological phenotyping can impact access to disease-modifying treatments in ATTR carriers.Semantic proximity Read ↗

Hereditary transthyretin amyloidosis: a myriad of factors that influence phenotypic variability.Semantic proximity Read ↗

A description of variant transthyretin amyloidosis (ATTRv) stage 1 patients and asymptomatic carriers in Spain: the EMPATIa study.Semantic proximity Read ↗

Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progressionSemantic proximity Read ↗

Hereditary transthyretin amyloidosis overview.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.